%0 Journal Article
%A Lorenzini, Luigi
%A Maranzano, Alessio
%A Ingala, Silvia
%A Collij, Lyduine E
%A Tranfa, Mario
%A Blennow, Kaj
%A Di Perri, Carol
%A Foley, Christopher
%A Fox, Nick C
%A Frisoni, Giovanni B
%A Haller, Sven
%A Martinez-Lage, Pablo
%A Mollison, Daisy
%A O'Brien, John
%A Payoux, Pierre
%A Ritchie, Craig
%A Scheltens, Philip
%A Schwarz, Adam J
%A Sudre, Carole H
%A Tijms, Betty M
%A Verde, Federico
%A Ticozzi, Nicola
%A Silani, Vincenzo
%A Visser, Pieter Jelle
%A Waldman, Adam
%A Wolz, Robin
%A Chételat, Gael
%A Ewers, Michael
%A Wink, Alle Meije
%A Mutsaerts, Henk
%A Gispert, Juan Domingo
%A Wardlaw, Joanna M
%A Barkhof, Frederik
%T Association of Vascular Risk Factors and Cerebrovascular Pathology With Alzheimer Disease Pathologic Changes in Individuals Without Dementia.
%J Neurology
%V 103
%N 7
%@ 0028-3878
%C [Erscheinungsort nicht ermittelbar]
%I Ovid
%M DZNE-2024-01148
%P e209801
%D 2024
%X Vascular risk factors (VRFs) and cerebral small vessel disease (cSVD) are common in patients with Alzheimer disease (AD). It remains unclear whether this coexistence reflects shared risk factors or a mechanistic relationship and whether vascular and amyloid pathologies have independent or synergistic influence on subsequent AD pathophysiology in preclinical stages. We investigated links between VRFs, cSVD, and amyloid levels (Aβ1-42) and their combined effect on downstream AD biomarkers, that is, CSF hyperphosphorylated tau (P-tau181), atrophy, and cognition.This retrospective study included nondemented participants (Clinical Dementia Rating < 1) from the European Prevention of Alzheimer's Dementia (EPAD) cohort and assessed VRFs with the Framingham risk score (FRS) and cSVD features on MRI using visual scales and white matter hyperintensity volumes. After preliminary linear analysis, we used structural equation modeling (SEM) to create a 'cSVD severity' latent variable and assess the direct and indirect effects of FRS and cSVD severity on Aβ1-42, P-tau181, gray matter volume (baseline and longitudinal), and cognitive performance (baseline and longitudinal).A total cohort of 1,592 participants were evaluated (mean age = 65.5 ± 7.4 years; 56.16
%K Humans
%K Alzheimer Disease: pathology
%K Alzheimer Disease: cerebrospinal fluid
%K Alzheimer Disease: diagnostic imaging
%K Male
%K Female
%K Aged
%K Risk Factors
%K Amyloid beta-Peptides: cerebrospinal fluid
%K Retrospective Studies
%K Cerebral Small Vessel Diseases: diagnostic imaging
%K Cerebral Small Vessel Diseases: complications
%K Cerebral Small Vessel Diseases: pathology
%K tau Proteins: cerebrospinal fluid
%K Peptide Fragments: cerebrospinal fluid
%K Middle Aged
%K Magnetic Resonance Imaging
%K Biomarkers: cerebrospinal fluid
%K Brain: pathology
%K Brain: diagnostic imaging
%K Atrophy: pathology
%K Amyloid beta-Peptides (NLM Chemicals)
%K tau Proteins (NLM Chemicals)
%K Peptide Fragments (NLM Chemicals)
%K amyloid beta-protein (1-42) (NLM Chemicals)
%K Biomarkers (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%2 pmc:PMC11450612
%$ pmid:39288341
%R 10.1212/WNL.0000000000209801
%U https://pub.dzne.de/record/272157